The microbiome has become one of the most influential frontiers in modern medicine, but the field still faces a fundamental problem: studies that appear to investigate the same disease often collect different clinical information, define outcomes in incompatible ways and analyze microbial data using methods that are difficult to compare. A new multidisciplinary consensus statement published in Nature Reviews Gastroenterology & Hepatology addresses this challenge by proposing minimum standards for the clinical metadata and end points that should accompany microbiome research.
The statement, developed through a Delphi consensus process, brings together experts from clinical medicine, gastroenterology, microbiology, bioinformatics, epidemiology and related disciplines. Delphi studies use repeated rounds of structured consultation to identify areas of agreement among specialists. In this case, the goal was not to impose a single experimental protocol, but to establish a common foundation that can make clinical microbiome studies more interpretable, reproducible and useful for patient care.
Microbiome research examines the communities of microorganisms living in and on the human body, particularly the bacteria, archaea, fungi, viruses and microbial genes found in the gastrointestinal tract. These organisms can influence immune activity, metabolism, intestinal barrier function and drug processing. Yet the composition of the microbiome can change dramatically according to diet, medication exposure, age, geography, stool transit time, illness severity and the method used to collect and store samples. Without detailed information about these factors, researchers may mistake a consequence of disease or treatment for a microbial cause.
The consensus statement therefore emphasizes the importance of recording clinical metadata alongside biological samples. Such metadata can include the participant’s diagnosis, disease duration, symptom profile, comorbidities, age, sex, nutritional status and relevant laboratory measurements. Medication history is also critical, particularly recent exposure to antibiotics, proton-pump inhibitors, laxatives, immunosuppressive drugs and other treatments known to alter microbial communities. Recording these variables allows investigators to distinguish disease-associated microbial patterns from changes driven by therapy or other clinical circumstances.
Lifestyle and sampling information can be equally decisive. Dietary intake, alcohol consumption, smoking, physical activity and recent infections may all affect microbial composition. The timing of sample collection, the interval since the last meal or bowel movement, stool consistency and the conditions used for transport and storage can influence the resulting molecular profile. The statement supports consistent documentation of these details because even small differences in pre-analytical handling can create apparent biological differences between study groups.
The authors also focus on the need for clearly defined clinical end points. A microbiome study may report changes in bacterial diversity or the abundance of a particular organism, but these measurements are not automatically meaningful to patients. Clinical end points should be specified in advance and linked to outcomes such as symptom improvement, disease remission, treatment response, relapse, hospitalization, complications or survival, depending on the condition being studied. Patient-reported outcomes and validated disease activity scores can provide information that sequencing data alone cannot capture.
This distinction is technically important because microbiome measurements are often treated as surrogate markers. A shift in alpha diversity, which describes richness and evenness within a sample, or beta diversity, which compares community composition between samples, may indicate that the microbiome has changed. However, a statistically significant change does not prove that the change is clinically beneficial, harmful or causally involved in disease. Connecting microbial features to robust clinical end points is essential if microbiome research is to move beyond association studies and support diagnostics, prognostic tools or therapeutic decisions.
The consensus further highlights the importance of describing laboratory and computational methods in sufficient detail. Researchers may use 16S ribosomal RNA gene sequencing to profile bacterial communities, shotgun metagenomic sequencing to examine the broader microbial genetic repertoire, or metatranscriptomics and metabolomics to investigate microbial activity and biochemical products. Each approach has different strengths and limitations. Primer selection, sequencing depth, reference databases, quality-control procedures, taxonomic classification and statistical pipelines can all affect the conclusions. Transparent reporting would make it easier to reproduce findings and evaluate why studies disagree.
For clinical translation, standardization also matters when studies compare samples across hospitals, countries or time periods. A shared minimum data set can support better integration of cohorts and improve the statistical power needed to identify reliable microbial signatures. It may also help researchers evaluate whether a proposed biomarker performs consistently in different populations rather than reflecting a local diet, laboratory workflow or prescribing pattern. The statement does not eliminate the need for specialized information in individual diseases, but provides a baseline upon which disease-specific protocols can be built.
The authors present the recommendations as a practical framework for improving the quality of future microbiome investigations. Their central message is that a stool sample, blood specimen or sequencing file cannot be interpreted in isolation: its scientific value depends on the clinical context, the collection process and the outcome against which it is measured. By encouraging multidisciplinary collaboration and more complete reporting, the consensus aims to narrow the gap between rapidly advancing microbiome science and dependable clinical evidence. If adopted widely, these minimum standards could make results easier to compare, strengthen validation studies and help determine which microbial discoveries genuinely matter for human health.
Subject of Research: Clinical metadata and end points in human microbiome studies
Article Title: Multidisciplinary Delphi consensus statement on minimal standards for clinical metadata and end points in microbiome studies
Article References: Schierwagen, R., Carraturo, F., Iyappan, A. et al. Multidisciplinary Delphi consensus statement on minimal standards for clinical metadata and end points in microbiome studies. Nature Reviews Gastroenterology & Hepatology (2026). https://doi.org/10.1038/s41575-026-01229-1
Image Credits: AI Generated
DOI: 10.1038/s41575-026-01229-1
Keywords: microbiome, clinical metadata, Delphi consensus, gastroenterology, microbiota, clinical end points, sequencing, reproducibility, precision medicine
